ALLO - Allogene Therapeutics, Inc.
Bank of America Corp DE bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,187,320 shares of the company's stock, valued at approximately $6,630,000. Bank of America Corp
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,446,668 shares of the company's stock after acquiring an additional 18,650,000 shares during the quarter.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.
Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,949 shares of the company's stock, valued at approximately $586,000. Deutsche Bank AG owned about 0.08% of Allogene
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 322,827 shares of the company's stock, valued at approximately $671,000. Connor Clark
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
Bank of America Corp DE lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 111.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,134,473 shares of the company's stock after acquiring an additional 1,127,145
Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 25.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,201,655 shares of the company's stock after acquiring an additional 243,839 shares during the quarter. Dimensional Fund Advisors
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2026.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has
FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel's Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a 97.7% Median Decrease in Plasma ctDNA at Day 45, Compared With a 26.6% Median Increase in the Observation Arm Cema-Cel Was Well-Tolerated, With Most Patients Managed in the Outpatient Setting and No Hospitalizations for Treatment-Related Adverse Events FDA Also Granted Fast Track Designation to Cema-Cel for the ALPHA3 Development Program RMAT and Fast Track Status Enable Enhanced FDA Engagement and Support Potential Expedited Development and Review Pathways SOUTH SAN FRANCISCO, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cemacabtagene ansegedleucel (cema-cel) for the treatment of adult patients with large B-cell lymphoma (LBCL) who, at the completion of first-line (1L) therapy, are in complete or partial response suitable for observation but test positive for minimal residual disease (MRD).
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HS ALLO-316 Demonstrated Robust Expansion and Tumor Infiltration Following Standard Lymphodepletion, Validating the Dagger ® Technology as a Next-Generation Allogeneic CAR T Platform SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of complete Phase 1 data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology.